Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma

Table 1 Background data of the study groups

	Egyptian			Japanese
	HCC (+)	HCC (–)	P	HCC (+)	HCC (–)	P
	n = 65	n = 106		n = 45	n = 128
Mean age (SD, yr)	57±11b	47±9	<0.001	66±10b	63±10	NS
Age <50 yr	16 (25)d	65 (61)	<0.001	3 (7)d	17 (13)	NS
Male	50 (77)	82 (77)	NS	38 (84)	87 (68)	0.024
Liver disease
Viral	61 (94)	96 (91)		44 (98)	107 (84)
HCV-related	59 (91)	92 (87)	NS	36 (80)	81 (63)	0.031
HBV-related	2 (3)1	4 (4)	NS	8 (18)1	28 (22)	NS
Non-viral	4 (6)	10 (9)	NS	1 (2)	20 (16)	0.010
Cirrhosis	46 (71)	45 (42)	<0.001	40 (89)	40 (31)	<0.001
Child’s C	25 (38)f	17 (16)	0.001	4 (9)f	1 (1)	0.017
Mean±(SD)
ALT (IU/L)	73±95	66±45	0.08	55±35	50±39	NS
Serum Albumin (g/L)	3.0±0.7	3.0±0.5	NS	3.6 ±0.5	4.2±0.4	<0.001
Platelet count×1 000/mL3	186±107h	89±53	0.001	130±51h	170±71	<0.001
AFP >10 ng/mL (+)	64 (99)	28 (26)	<0.001	30 (67)	23 (18)	<0.001
PIVIKA>40 mAU/L (+)	51 (79)	38 (36)	<0.001	16 (36)	27 (21)	0.047

^bP<0.001,

^dP<0.001,

^fP<0.001,

^hP<0.001 vs Japannese,

¹P = 0.001.